Martine Gardembas

Response to Imatinib Mesylate in Patients with Chronic Myeloproliferative Diseases with Rearrangements of the Platelet-Derived Growth Factor Receptor Beta

Jane F. Apperley, Martine Gardembas, Junia V. Melo et al. · New England Journal of Medicine · 2002 · 631 citations · Full text

Medicine, Hematology, Molecular Genetics +16

Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years

Philippe Rousselot, Françoise Huguet, Delphine Réa et al. · Blood · 2006 · 530 citations

Pharmacy, Hematology, Pharmacotherapy +3

Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia

Gabriel Étienne, Joëlle Guilhot, Delphine Réa et al. · Journal of Clinical Oncology · 2016 · 494 citations

Medicine, Hematology, Pharmacotherapy +15

Infections in 252 Patients with Common Variable Immunodeficiency

Éric Oksenhendler, Laurence Gérard, Claire Fieschi et al. · Clinical Infectious Diseases · 2008 · 478 citations

Life Sciences, Immunology, Internal Medicine +9

Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease

Philippe Rousselot, Aude Charbonnier, Pascale Cony‐Makhoul et al. · Journal of Clinical Oncology · 2013 · 409 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13